NRAS and melanoma: These findings are consistent with an analysis of 699 unselected (i.e. BRAF wild-type and mutated) melanomas using the same 46-gene cancer panel, where, after BRAF mutations (41% of cases), NRAS (22%) and TP53 (17%) were the next commonest mutations.22 In our BRAF wild-type population, four cases tested by NGS had a BRAF mutation that had not been detected during initial screening by hotspot mutation testing (Fig. 1a, Supplementary Table 2).